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DObjective: Postoperative atrial fibrillation (POAF) is the most frequent complication arising after cardiac sur-
gery, occurring in 30% of cases. Amiodarone is the most effective drug for prophylaxis and treatment. However,
because of significant extracardiac side effects, only high-risk patients are eligible for prophylactic amiodarone
therapy. We performed a randomized prospective study of 100 patients undergoing cardiac surgery with
epicardial application of amiodarone-releasing hydrogel to determine the effectiveness of preventing POAF.
Methods: After institutional review board approval, 100 patients, from January 2012 to July 2013, who had
undergone cardiac surgery, were randomized to 2 equal groups. The study group received poly-based hydrogel
with amiodarone sprayed diffusely over the epicardium. The control group underwent the procedure without the
spray. Continuous telemetry monitored for POAF, and amiodarone levels in the atria, plasma, and tissue were
measured postoperatively. Daily electrocardiographic parameters were measured until postoperative day 14.
Results: The incidence of POAF was significantly less in the study group, with 4 of 50 patients (8%) incurring
atrial fibrillation compared with 13 of 50 patients (26%) in the control group (P<.01). The mean amiodarone
concentrations in the atria (12.06  3.1) were significantly greater than those in the extracardiac tissues
(1.32  0.9; P<.01). The plasma amiodarone levels remained below the detection limit (<8 mg/mL) during
the 14 days of follow-up. Bradycardia was observed less in the study group (76  29) than in the control group
(93  18; P<.01).
Conclusions: Epicardial application of amiodarone-releasing adhesive hydrogel is a less invasive, well-
tolerated, quick, and effective therapeutic option for preventing POAF at minimal risk of extracardiac adverse
side effects. (J Thorac Cardiovasc Surg 2014;148:939-43)Postoperative atrial fibrillation (POAF) is the most frequent
complication arising after cardiac surgery, occurring in 30%
of cases.1,2 It increases patient mortality and morbidity,
hospitalization duration, and healthcare resource usage.
Currently, the available conventional therapies for
preventing POAF are suboptimal. Amiodarone, a class III
antiarrhythmic medicine, is the most effective drug
for prophylaxis and treatment. Clinical studies have
demonstrated the efficacy of oral and intravenous
amiodarone therapy to prevent POAF. Despite its
superior efficacy, amiodarone therapy has several
disadvantages, including the requirement of a loading
period, interactions with many other drugs, and, most
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The Journal of Thoracic and Caas thyroid dysfunction, pulmonary toxicity, and hepatic
toxicity.3,4 These have been, in part, attributed to the
relatively high drug concentrations required with systemic
administration.
The concept of local amiodarone delivery to the myocar-
dium has been investigated in several animal studies using
intrapericardial infusion of amiodarone solutions.5,6 They
were able to minimize the ventricular and extracardiac
adverse effects of amiodarone and made a loading period
superfluous. Although the results are encouraging, most
arrhythmias require a longer treatment duration. Long-
term catheter-based intrapericardial infusion could increase
the risk of infection and fibrosis. This approach is also not
applicable to the postoperative patient, because the
pericardium is usually left open and in communication
with a mediastinal drain. Along with bleeding and
effusions, any drug solution instilled at surgery would be
rapidly evacuated. A few studies researching the effective-
ness of the topical application of a biodegradable disc with
amiodarone or amiodarone-eluting bilayered patch have
reported encouraging results.7,8 However the amount of
exposure to the atrial epicardial surface is often limited
using those applications. Biatrial epicardial application of
drug-releasing hydrogel might offer the advantage of a
more localized (biatrial-targeted) drug delivery, because,rdiovascular Surgery c Volume 148, Number 3 939
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AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
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Ddespite diffusion to other heart chambers through leakage to
the pericardial fluid, the amiodarone concentration of the
biatrial myocardium remains very high.
CoSeal Surgical Sealant (BaxterHealthcare,Deerfield, Ill)
is used in a wide range of surgical specialties, including
cardiac procedures, primarily for prevention of pericardial
adhesions and anastomotic bleeding. These agents consist
of 2 biodegradable synthetic polyethylene glycol (PEG)
polymers that are mixed at application, forming a strong
hydrogel that vigorously adheres to tissue.9 These properties
make this biomatrix attractive as a vehicle for local drug
delivery. Lidocainemixedwith this hydrogel has been shown
to reduce postoperative pain after breast augmentation.10 The
hydrogel has also been used to deliver nerve growth factor,
stem cells, and chemotherapeutic agents.11 From these
studies, we reasoned that the addition of amiodarone to this
hydrogel would produce a drug-releasing matrix capable of
suppressing atrial tachyarrhythmias and the systemic drug
levels would remain low, even in the presence of effusion
or pericardial drainage. The purpose of the present prospec-
tive study was to evaluate the efficacy of amiodarone-loaded
hydrogels applied to the atria to prevent POAF.METHODS
A total of 100 patients scheduled to undergo coronary artery bypass
grafting (CABG) from January 2012 to July 2013 were randomized and
prospectively enrolled in the present study. The institutional review board
and ethical research committee approved the study, and all patients
provided informed consent. Patients were excluded if they had a history
of pacemaker or automatic internal cardiac defibrillator placement or if
significant preoperative events developed, such as cardiogenic shock or
ventricular tachyarrhythmia. The 100 patients (60 men, 40 women; mean
age, 52  9 years), who were undergoing conventional on-pump CABG,
were randomized to 2 equal groups. The study group received
CoSeal-based hydrogel with amiodarone sprayed diffusely over the biatrial
epicardium. The control group underwent CABG without amiodarone
spraying (Table 1).
A sprayable polymeric matrix, CoSeal Surgical Sealant was obtained
from Baxter Healthcare. The kit includes 2 synthetic PEGs: a dilute
hydrogen chloride solution and a sodium phosphate/sodium carbonate
solution. Amiodarone hydrochloride powder (Sigma-Aldrich, St Louis,
Mo), 1 mg/kg bodyweight, was first added to the PEG powder and then
mixed with the solutions until the powder had completely dissolved. These
components form a hydrogel. All patients primarily underwent on-pump
CABG. Triple radiofrequency pulmonary vein epicardial circumferential
isolation was performed in 5 patients who had been diagnosed with
paroxysmal atrial fibrillation (AF; 3 in the study group, 2 in the control
group). All patients underwent dissection of the superior vena cava–atrial
junction area and the free left atrial anterior wall, which was adjacent to
the transverse sinus (Backmann’s bundle area). Temporary epicardial atrial940 The Journal of Thoracic and Cardiovascular Surgand ventricular pacing wires were inserted in all patients at the end of
surgery. Before the sternum was closed, the hydrogel was sprayed
diffusely using a carbon dioxide driver set over the right atrial lateral
wall, left atrial appendage, and transverse sinus area. The pericardium
was approximated with interrupted sutures, and a single mediastinal chest
tube was placed retromediastinally above the pericardium. Myocardial
venous blood sampling was obtained from the coronary venous sinus under
fluoroscopic control during postoperative day 3. Also, right atrial
endomyocardial biopsy was performed from areas adjacent to the fossa
ovalis for measurement of the myocardial amiodarone concentration.
Finally, abdominal extraperitoneal adipose tissue within the chest tube
site was biopsied during chest tube removal on postoperative day 3. The
amiodarone plasma concentrations were also measured using blood drawn
from a peripheral vein during postoperative days 2 and 5. The amiodarone
and desethylamiodarone assays were done using the standard method of
high-performance liquid chromatography (HP-Series 1090; Hewlett
Packard, Palo Alto, Calif). A cardiac enzyme panel was measured on
postoperative days 1, 3, and 5 and before discharge to monitor local atrial
myocardial injury. Continuous telemetry was used to monitor for POAF.
Daily electrocardiographic parameters (RR, PQ, and QT intervals,
maximal intervals between the peak and end of the T wave, and P and
QRS widths) were measured until postoperative day 14. Postoperatively,
the patients in the control group received either intravenous or oral
amiodarone for new-onset atrial fibrillation. Electrical cardioversion was
performed before hospital discharge for any patient who was not in normal
sinus rhythm.
All values are presented as the mean  standard deviation. Statistical
analysis comparing the data between the 2 groups was performed with
the chi-square test for categorical variables. Continuous variables were
compared using 2-tailed Student t tests and the Kruskal-Wallis test, as
appropriate. The collected data were analyzed using the number cruncher
statistical systems software (NCSS, Kaysville, Utah).RESULTS
No epicardial amiodarone hydrogel-related complica-
tions occurred. The greatest incidence of troponin T
detection was observed in 2 patients (2%) in the study
group with preoperative acute myocardial infarction.
Transient bradycardia requiring temporary pacing devel-
oped in 7 patients in the study group. The overall hospital
mortality was 1%. Stroke occurred in 1 patient (1%), and
5 patients underwent reoperation for bleeding (5%). The
mean follow-up period was 6  9 months (range, 1-14).
The incidence of POAF was significantly less in the study
group, with 4 of 50 patients (8%) developing POAF
compared with 13 of 50 patients (26%) in the control group
(P< .01). In the study group, the coronary venous sinus
blood concentration of amiodarone (10.09  3.6 mg/mL)
was far greater than that in the peripheral plasma
(1.43  1.6 mg/mL; P< .01). The plasma concentrations
of both amiodarone and desethylamiodarone remained
below detection limits (<8 mg/mL) during the 14 days of
follow-up. The right atrial myocardium concentration of
desethylamiodarone (12.06  3.1 mg/g) was significantly
greater than that in the abdominal adipose tissue
(1.32  0.9 mg/g; P<.01). The mean heart rate averaged
76  29 beats/min within 7 days in study group compared
with 93  18 beats/min in the control group (P< .01).
The QT intervals increased from 401  44 ms beforeery c September 2014
TABLE 1. Patient demographic characteristics
Characteristic Study group Control group Total
Patients (n) 50 50 100
Median age (y) 52  9.1 51  7.9 —
Sex —
Male 29 31
Female 21 19
Previous MI 14 (28) 13 (26) 27
CHF 9 (18) 12 (24) 21
Preoperative AF 3 (6) 2 (4) 5
Preoperative IABP 3 (6) 4 (8) 7
Previous CABG 4 (8) 6 (12) 10
Previous PCI 27 (54) 24 (48) 51
Hypertension 16 (32) 11 (22) 27
Diabetes 17 (34) 19 (38) 36
Chronic lung disease 22 (44) 23 (46) 45
PVD 6 (12) 7 (14) 13
Previous stroke 5 (10) 8 (16) 13
Smoking (previous 6 mo) 35 (70) 39 (78) 74
BMI>30 kg/m2 21 (42) 19 (38) 40
b-Blockers 11 (22) 14 (28) 25
Calcium channel blockers 5 (10) 7 (14) 12
Aspirin 31 (62) 37 (74) 65
Data presented as n (%), unless otherwise noted. Univariate P ¼ NS for all items.
MI, Myocardial infarction; CHF, congestive heart failure; IABP, intra-aortic balloon
pump; CABG, coronary artery bypass grafting; PCI, percutaneous coronary interven-
tion; PVD, peripheral vascular disease; BMI, body mass index; AF, atrial fibrillation.
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therapy, and the rate corrected QT intervals increased from
452  43 ms to 463  37 ms (P ¼ .06).DISCUSSION
The main finding of the present study was that biatrial
epicardial application of amiodarone-releasing hydrogel
was effective in preventing and lowering the incidence of
POAF. The treatment was safe and well tolerated and
yielded persistently greater drug concentrations in the atria
compared with the extracardiac tissues. The treatment was
easy to apply and displayed both biodegradability and
immediate tissue adherence, allowing more localized drug
delivery.
Atrial fibrillation is a common and undesirable event after
cardiac surgery and is an important source of patient
morbidity and increased resource usage. The incidence of
AF has been reported at 27.6% after CABG, 48.8% after
mitral valve replacement, 32.9% after aortic valve replace-
ment, and greater after combined procedures.1 Postoperative
AF has been associatedwith an increased hospital stay, early
stroke risk, and a reduction in in-hospital and long-term
survival.12 Although promising nonpharmacologic thera-
pies, in particular, ablation procedures, have been
developed, pharmacotherapy remains the cornerstone of
AF treatment. At present, the most frequently applied drug
worldwide for maintaining sinus rhythm in patients withThe Journal of Thoracic and CaAF is amiodarone, a highly lipophilic, multi-ion channel
blocker.13 Compared with other contemporary clinically
used antiarrhythmic agents, it combines high effectiveness
with a low risk of Torsades de pointes. However, the major
drawbacks of amiodarone involve its multiple systemic
side effects, including thyroid, pulmonary, hepatic, and
dermatologic toxicity, and its complex and inconvenient
pharmacokinetic profile, including slow and quite extensive
tissue accumulation and very long half-life. To improve
the effectiveness of the drug and minimize its systemic
toxicity, 3 alternative applications for epicardial amio-
darone delivery have been developed: intrapericardial-
infused amiodarone solutions, epicardially sprayed in
situ amiodarone-releasing adhesive hydrogels, and epicar-
dially sutured amiodarone-eluting bilayered patches or
discs.14,15 A number of studies have investigated local
drug delivery of antiarrhythmic agents, including
lidocaine, digoxin, amiodarone, b-blockers, procainamide,
ibutilide, sotalol, and flecainide.16,17 The pharmacokinetic
advantages and significant effects on atrial electro-
physiologic parameters were invariably demonstrated.
Intrapericardial amiodarone infusion is ideally suited for
noncardiac surgery patients with an intact pericardial sac,
because it provides a natural drug reservoir and space for
epicardial drug delivery. A recent study showed
intrapericardial delivery of ibutilide, sotalol, and
amiodarone did not result in a greater AF conversion rate
or increased risks of infection, local myocardial fibrosis, or
ventricular arrhythmia.18 This resulted in part from the
amiodarone delivery effects on global ventricular electro-
physiology causing QT interval prolongation and a shorter
infusion duration. The epicardial amiodarone-eluting
bilayered patches or discs allow more localized release of
drugs, minimize drug leakage to the pericardial fluid to
prevent disruption of ventricular electrophysiology, and
produce long-term, sustained drug delivery by the biode-
gradable matrix. Nevertheless, epicardial patch application
was considered somewhat difficult and time-consuming
and has limited acceptance at the left atrial wall because
of the anatomic complexity of the left atrium. The epicar-
dially sprayed, in situ, PEG-based, amiodarone-releasing
adhesive hydrogels used in the present study are biodegrad-
able amiodarone-loaded matrixes that adhere to the
epicardium and are able to achieve sustained therapeutic
myocardial concentrations. We found the application to be
technically simple and quick, and, most importantly, the
hydrogel diffusion covered both atrial surfaces without
adding any complications. The thin atria seem to be suitable
for this delivery method, because of their high surface
area/wall thickness ratio.
The present study is the first to clinically demonstrate that
biatrial epicardial application of amiodarone-releasing
hydrogel significantly reduces the incidence of POAF
compared with the control group. The delivery methodrdiovascular Surgery c Volume 148, Number 3 941
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atrial tissue and thus becomes locally effective for the
atrium. The atrial concentration of amiodarone was far
greater than that in the other organs, and the blood concen-
tration of amiodarone was below detectable levels. This
local high amiodarone concentration was attributed to the
intracardial diffusion. Bolderman and colleagues8 reported
that application of amiodarone-releasing hydrogel to the
atrium produced 10-fold greater epicardial drug concentra-
tions than did endocardial concentrations in an animal
study. The present study also found this delivery system
minimized drug release into the pericardial fluid, did not
appear to disturb the ventricular electrophysiology, and
enabled longer lasting site-specific drug delivery. No QT/
rate corrected QT interval prolongation, Torsades de
pointes, or significant clinical bradycardia developed.
The PEG-based hydrogel used in the present study
displayed both biodegradability and immediate tissue
adherence during in situ formation, allowing a more
localized drug delivery. Moreover, the clinical safety of
epicardial application of this hydrogel has been previously
demonstrated.19 Amiodarone loading did not affect hydro-
gel tolerability in the present study. Amiodarone extravasa-
tion is not uncommon with peripheral vein infusions, and it
can potentially cause serious injury and permanent harm
such as tissue necrosis. The toxic effects result from the
low pH of the solution (pH, 3.5-4.5) and the additives
polysorbate and benzyl alcohol. Previous animal studies
provided in vivo evidence that topical amiodarone applica-
tion has no direct toxic affect on the atrial myocardium;
however, little is known about the structure and functional
impairment of the atrial myocardium after epicardial
amiodarone application in humans. In the present study,
no significant changes were seen in the positive value of
troponin T release between the study and control groups,
and the study group did not appear to have a greater
incidence of atrial tachyarrhythmia. This compelling
clinical evidence has demonstrated that the epicardial
amiodarone application carries an extremely low risk of
direct tissue injury. The hydrogel used in the present study
also reduced epicardial inflammation, explaining its
efficacy in preventing pericardial adhesions after cardiac
surgery.
The present study had several limitations. First, we did
not evaluate the dose effects of the sustained release of
amiodarone from the adhesive hydrogels or the kinetics of
amiodarone after its release. Darsinos and colleagues6 sug-
gested ‘‘intracardiac movement’’ was a possible mechanism
for absorption of pericardial application of amiodarone
from that space into the heart tissue. We speculate that a
similar mechanism plays an important role in elevating
the tissue concentration of amiodarone in the atrium,
although the precise mechanism was not investigated in
our study. Second, only 1 dose of amiodarone hydrochloride942 The Journal of Thoracic and Cardiovascular Surgpowder and 1 type of hydrogel was used to prepare the
drug-loaded hydrogels in the present study. Variations in
the hydrogel formulations by changing the polymer
chemistry or the altering drug dose or adding epicardial
steroid application could result in different drug release
characteristics. Third, the present study design was selected
in accordancewith pilot experiments demonstrating that the
surgical sealant did not contribute to the antiarrhythmic or
anti-inflammatory effects. No amiodarone was present in
the hydrogel applied as a placebo in the control group.
Finally, it was more captivating to investigate the continu-
ously monitored biatrial electrophysiologic parameters
perioperatively and to measure the atrial effective refractory
periods and conduction times.CONCLUSIONS
Epicardial application of amiodarone-releasing adhesive
hydrogel is a less invasive, well-tolerated, quick, and
effective therapeutic option for preventing POAF. These
results indicate that this method could be promising in the
prevention of POAF with a lower risk of ventricular and
systemic side effects compared with intravenous and oral
amiodarone administration.References
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